Search

Search Constraints

You searched for: Subject Breast--Cancer--Treatment Remove constraint Subject: Breast--Cancer--Treatment Start Over

Search Results

5. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation